Table 1 Clinical data of CAR-T cell products in hematologic malignancies
From: Challenges and strategies associated with CAR-T cell therapy in blood malignancies
Products | Target Antigen | Indications | Patients (n) | ORR/CR | PFS/OS | MFU, | Reference |
|---|---|---|---|---|---|---|---|
Ciltacabtagene autoleucel | BCMA | R/R MM | R/R MM patients(97) | 97.9%/82.5% | 54.9%and 70.4%(27mo) | 28 mo | 2 |
Idecabtagene vicleucel | BCMA | R/R MM | R/R MM patients(128) | 73%/33% | 27.3%/64%(12mo) | 13.3 mo | 3 |
Lisocabtagene maraleucel | CD19 | R/R large B-cell lymphoma | R/R large B-cell lymphoma (269) | 73%/53% | 44%/58%(12 mo) | 18.8mo | 4 |
Brexucabtagene autoleucel | CD19 | R/R MCL | R/R MCL(33) | 91%/79% | 51%(12mo)/ 61% (12MO) | - | 5 |
Brexucabtagene autoleucel | CD19 | R/R B-cell precursor ALL | R/R B-cell precursor ALL (65) | 71% /56% | 12.8mo/18.2 | 16.4mo | 6 |
Axicabtagene ciloleucel | CD19 | R/R large B-cell lymphoma | R/R large B-cell lymphoma(180) | 83%/65% | 41%/61%(24mo) | 24.9 | 7 |
Axicabtagene ciloleucel | CD19 | R/R follicular lymphoma | follicular lymphoma(124) and marginal zone lymphoma(24) | 92%/74% | Â | 17.5 | 8 |
Tisagenlecleucel | CD19 | R/R B-cell precursor ALL | r/r B-cell ALL(75) | 81%/60% | 90%/82%(6mo) | 13.1 | 9 |
Tisagenlecleucel | CD19 | R/R large B-cell lymphoma | R/R diffuse large B-cell lymphoma(93) | 52%/40% | 83%/49%(12mo) | 14 | 10 |